Myalepta (Metreleptin)

Metreleptin, the active ingredient in Myalepta, is a leptin analog presented as a recombinant protein for subcutaneous use. It is indicated for the treatment of generalized and partial lipodystrophy, conditions characterized by deficient endogenous leptin and associated metabolic disturbances.

GNH USA supplies Myalepta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards, ensuring product integrity throughout the cold‑chain logistics required for biologic injectables. Our global network facilitates timely delivery to meet clinical needs.

Myalepta (metreleptin) acts on the leptin signaling pathway to address metabolic disorders associated with lipodystrophy.

- Generalized lipodystrophy: improves metabolic control and reduces hypertriglyceridemia. - Partial lipodystrophy: helps normalize leptin levels and improve insulin sensitivity. - Metabolic abnormalities linked to leptin deficiency: aids in controlling dyslipidemia and hepatic steatosis.

Adverse reactions may occur with metreleptin therapy.

Common Side Effects: - Injection site erythema or pain. - Headache. - Nausea. - Fatigue.

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylaxis. - Development of anti‑leptin antibodies. - Pancreatitis.

Use of Myalepta requires careful clinical monitoring.

- Triglyceride monitoring: check serum triglycerides regularly. - Infection risk: assess for active infections before initiation. - Autoimmune disease: evaluate for pre‑existing autoimmune conditions. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Pregnancy/Breastfeeding: safety not established; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metreleptin may interact with other therapies.

Major Interactions (Avoid): - Live vaccines: avoid concurrent use due to potential altered immune response. - Other leptin analogs: do not co‑administer. - Immunosuppressants: may blunt therapeutic effect.

Moderate Interactions (Monitor Closely): - Insulin therapy: glycemic control may improve, requiring dose adjustment. - Oral hypoglycemics: monitor blood glucose levels. - Corticosteroids: may affect endogenous leptin levels and require observation.